The Wall Street Journal recently analyzed the pricing data of drugs and found the cancer drug Gleevec, which went generic in 2016, could be bought for as little as $55 a month through the manufacturer, but CVS Health (CVS) and Cigna (CI) charge $6,600 a month or more for the prescriptions, Joseph Walker of The Wall Street Journal. Across a selection of generic drugs, CVS and Cigna’s prices were at least 24 times higher than what the manufacturer charges, the Journal found. UnitedHealth Group’s prices were 3.5 times as much, according to an analysis compiled by 46brooklyn Research.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CVS:
- Walmart (NYSE:WMT) Eyes Health Care Sector with Massive Investment
- CVS Health management to meet with Mizuho
- CVS Health price target lowered to $82 from $85 at Piper Sandler
- Walmart asks pharmacists to take voluntarily wage cuts, Reuters says
- CVS Health (NYSE:CVS) Stock: 3 Reasons Why It’s as Attractive as Ever